Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409573 | 0.93 | ALDH1A1 (0.46) | PTPN1RXRAGPR84ALDH1A1RAB9A | |
| SCHEMBL18409568 | 0.84 | GPR84 (0.57) | PTPN1GPR84ALDH1A1RAB9A | |
| SCHEMBL18409341 | 0.83 | RXRA (0.49) | RXRACDK4CCND1 | |
| SCHEMBL18409680 | 0.82 | GPR84 (0.63) | PTPN1GPR84ALDH1A1RAB9ACDK4 | |
| SCHEMBL18409640 | 0.81 | HTR1A (0.47) | RXRACDK4CCND1 | |
| SCHEMBL18409675 | 0.79 | GPR84 (0.53) | PTPN1RXRAGPR84CDK4CCND1 | |
| SCHEMBL18409572 | 0.78 | PTPN1 (0.50) | PTPN1RXRAGPR84ALDH1A1RAB9A | |
| SCHEMBL18409579 | 0.78 | GPR84 (0.61) | PTPN1GPR84ALDH1A1RAB9A | |
| SCHEMBL18409677 | 0.78 | GPR84 (0.58) | PTPN1GPR84ALDH1A1RAB9ACDK4 | |
| SCHEMBL18409683 | 0.78 | GPR84 (0.58) | PTPN1GPR84ALDH1A1RAB9ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY | 2020-11-24 | — | — | US | disclosed |
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | VHL, TP53, CD44 | PTPN1 2437/4885RXRA 172/4885GPR84 2974/4885 |
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | OXA1L, PDCD1, MCL1 | PTPN1 839/4885RXRA 1247/4885GPR84 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.